FDAnews Drug Daily Bulletin

To meet the dual challenges of drug discovery — developing new compounds faster and at less cost — drugmakers should consider forming more integrated partnerships where company staff and academic scientists work side-by-side, one expert suggests. “It’s the best way to ensure benefit on investment,” Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development, said.
Clinical Trials Advisor